Abstract:Background: Metabolic dysfunction-associated steatohepatitis (MASH; formerly nonalcoholic steatohepatitis) is the inflammatory form of metabolic dysfunction-associated steatotic liver disease (formerly nonalcoholic fatty liver disease). MASH is a progressive disease associated with increased risk for many hepatic and extra-hepatic complications such as cirrhosis, hepatocellular carcinoma, the requirement for liver transplantation, and cardiovascular (CV)-related and kidney-related complications. It is important to understand the clinical and economic burden of MASH. Objectives: To assess and compare the clinical and economic burdens of MASH in adults with the non-MASH population in a real-world setting. Methods: This observational, retrospective study used the Healthcare Integrated Research Database (HIRD), which contains health care claims data for commercially insured and Medicare Advantage health plan members across the United States. All-cause, CV-related, and liver-related medical costs and health care resource utilization were evaluated in patients with at least 2 diagnoses of MASH during the patient identification period (October 1, 2016, to April 30, 2022) and compared with a non-MASH cohort 1:1 matched on age, Quan Charlson Comorbidity Index, region of residence, and health plan type and length of enrollment. Generalized linear regression with negative binomial and γ distribution models were used to compare health care resource utilization and medical costs, respectively, while controlling for confounders. Covariate-adjusted all-cause, CV-related, and liver-related hospitalization rate ratios and medical cost ratios were assessed and compared for the MASH and matched non-MASH cohorts. Results: A total of 18,549 patients with MASH were compared with 18,549 matched patients in the non-MASH cohort. After adjusting for covariates, MASH was associated with significantly higher rates of hospitalization and higher medical costs compared with the non-MASH cohort. When compared with the non-MASH cohort, patients with MASH had 1.22 (95% CI = 1.15-1.30; P < 0.0001) times higher rates of all-cause hospitalization, 1.13 (95% CI = 1.03-1.24; P = 0.008) times higher rates of CV-related hospitalization, and 7.22 (95% CI = 4.91-10.61; P < 0.0001) times higher rates of liver-related hospitalization. Similarly, all-cause medical costs were 1.26 (95% CI = 1.22-1.30; P < 0.0001) times higher, CV-related medical costs were 1.66 (95% CI = 1.59-1.73; P < 0.0001) times higher, and liver-related medical costs were 7.79 (95% CI = 7.42-8.17; P < 0.0001) times higher among patients with MASH. Conclusions: Compared with those of the non-MASH cohort with similar age, Quan Charlson Comorbidity Index, health plan, region of residence, and duration of enrollment, patients with MASH had significantly higher all-cause, CV-related, and liver-related hospitalizations and medical costs.

Global Trend of MASH-associated Liver Cancer A Systematic Analysis from the Global Burden of Disease 2021

Worldwide burden of liver cancer due to metabolic dysfunction-associated steatohepatitis from 1990 to 2019: insights from the Global Burden of Disease study

Molecular mechanisms in MASLD/MASH related HCC

MASLD-Related HCC—Update on Pathogenesis and Current Treatment Options

Global incidence trends in primary liver cancer by age at diagnosis, sex, region, and etiology, 1990‐2017

Global burden trends of MAFLD‐related liver cancer from 1990 to 2019

Metabolic Dysfunction-Associated Steatohepatitis and Progression to Hepatocellular Carcinoma: A Literature Review

Global Trends and Inequalities of Liver Complications Related to Metabolic Dysfunction‐Associated Steatotic Liver Disease: An Analysis From 1990 to 2021

Envisioning how to advance the MASH field

Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors

Study on the central action of neuromuscular blocking agents.

MASLD-Related HCC: A Comprehensive Review of the Trends, Pathophysiology, Tumor Microenvironment, Surveillance, and Treatment Options

Abstract 286: Forecast of the Incidence and Etiology of Liver Cancer in Taiwan, Japan, United States, and United Kingdom: Toward Harmonization of East and West

Anti‐apoptotic action of hydrogen sulfide is associated with early JNK inhibition

MASH as an emerging cause of hepatocellular carcinoma: current knowledge and future perspectives

Global burden of nonalcoholic steatohepatitis-related liver cancer, 1990–2019: a systematic analysis for the GBD 2019

Epidemiology of Metabolic Dysfunction-Associated Steatotic Liver Disease

Prevalence of at‐risk MASH, MetALD and alcohol‐associated steatotic liver disease in the general population

Evaluating the burden of illness of metabolic dysfunction-associated steatohepatitis in a large managed care population: The ETHEREAL Study

A prospective study on the prevalence of at‐risk MASH in patients with type 2 diabetes mellitus in the United States

Global Trend of Aetiology-Based Primary Liver Cancer Incidence from 1990 to 2030: a Modelling Study